214
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Effect of 2-(4-aminophenylmethyl)-6-hydroxy-3,4-dihydronaphthalen-1(2H)-one on all-trans and 13-cis-retinoic acid levels in plasma quantified by high perfomance liquid chromatography coupled to tandem mass spectrometry

, , , , , & show all
Pages 219-226 | Received 01 Jun 2004, Accepted 25 Jun 2004, Published online: 03 Oct 2008

References

  • Bollag W In: Saurat TH, editor. Retinoids: New trends in research and therapy. Basle: Karger; 1985. p 274.
  • Van Wauwe JP, Coene MC, Goossens J, Van Nyen G, Cools W, Lauwers W. Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans-retinoic acid. J Pharmacol Exp Ther 1988;245(2):718–722.
  • Van Wauwe JP, Coene MC, Goossens J, Van Nyen G, Cools W, Lauwers W. Effect of cytochrome P-450 inhibitors on the in vivo metabolism of all trans-retinoic acid. J Pharmacol Exp Ther 1990;252(1):365–369.
  • Leo MA, Lida S, Lieber CS. Retinoic acid metabolism by a system reconstituted with cytochrome P450. Arch Biochem Biophys 1984;234:305–312.
  • Leo MA, Lasker Jl, Raucy JL, Cho-il K, Black M, Lieber CS. Metabolism of retinol and retinoic acid by human liver cyto- chrome P450 IIC8. Arch Biochem Biophys 1989;15:305–312.
  • Roberts ES, Vaz ADN, Coon MJ. Role of isozymes of rabbit microsomal cytochrome P450 in the metabolism of retinoic acid, retinol and retinal. Mol Pharmacol 1992;41:427–433.
  • Martini R, Murray M. Participation of P4503A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation. Arch Biochem Biophys 1993;303:17–66.
  • Raner GM, Vaz ADN, Coon MJ. Metabolism of all-trans, 9-cis and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhi- bition of retinoic oxidation by citral. Mol Pharmacol 1996; 49:515–522.
  • White JA, Beckett-Jones B, Guo YD, Dilworth J, Bonasoro J, Jones G, Petkovich M. cDNA cloning of human retinoic acid- metabolizing enzyme (hP450RAI) identifies a novel family of cytochromes P450 (CYP26). J Biol Chem 1997;272:18538–18541.
  • White JA, Guo YD, Baetz K, Beckett-Jones B, Bonasoro J, Hsu KE, Dilworth J, Jones G, Petkovich M. Identification of the retinoic acid-inducible all-trans-retinoic acid 4-hydroxylase. J Biol Chem 1996;271:29922–29927.
  • Smith HJ, Nicholls PJ, Simons C, LeLain R. Inhibitors of steroidogenesis as agents for the treatment of hormone- dependent cancers. Exp Opin Ther Pat 2001;11:789–824.
  • Kuijpers A, Van Pelt J, Bergers M, Boegheim P, Den Bakker J, Siegenthaler G, Van de Kerkhof P, Schalkwijk J. The effect of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin. Br J Dermatol 1998;139:380–389.
  • Van Pelt J, De Jong E, De Bakker E, Van de Kerkhof P. Effects of systemic treatment with liarozole on cutaneous inflam- mation, epidermal proliferation and differentiation in exten- sive plaque psoriasis. Skin Pharmacol Appl Skin Physiol 1998;11:70–79.
  • Dijkman GA, Fernandex del Moral P, Bruynseels J, De Porte P, Denis L, Debruyne F. Liarozole (R75251) in hormone- resistant prostate cancer patients. Prostate 1997;33:26–31.
  • Debruyne R, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, Denis L, Marberger JM, Brune D, Rassweler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P. Liarozole-A novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate. Urology 1998;52:72–81.
  • Denis L, Debruyne F, De Porre P, Bruynseels J. Early clinical experience with liarozole (Liazal(TM)) in patients with progressive prostate cancer. Eur J Cancer 1998;34:469–475.
  • Miller W. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998;83:1471–1482.
  • O’Bryne KJ, Han C, Mitchell K, Lane D, Carmichael J, Harris AI, Talbot DC. Phase II study of liarozole in advanced non- small cell lung cancer. Eur J Cancer 1998;34:1463–1466.
  • Schwartz EL, Hallam S, Gallagher RE, Wiernik PH. Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukaemia. Biochem Pharmacol 1995;50:923–928.
  • Stoppie P, Borgers M, Borghgraef P, Dillen L, Goossens J, Sanz G, Szel H, Van Hove C, Van Nyen G, Nobels G, Vanden Bossche H, Venet M, Willemsens G, Van Wauwe J. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoi- dal effects in rodents. J Pharmacol Exp Ther 2000;293:304–312.
  • Le Borgne M, Marchand P, Le Baut G, Ahmadi M, Smith HJ, Nicholls PJ. Retinoic acid metabolism inhibition by 3-azoly- methyl-1H-indoles and 2,3 or 5-(a-azolylbenzyl)-1H-indoles. J Enz Inhib Med Chem 2003;18:155–158.
  • Kirby AJ, LeLain R, Maharlouie F, Mason P, Nicholls PJ, Smith HJ, Simons C. Inhibition of retinoic acid metabolising enzymes by 2-(4-aminophenylmethyl)-6-hydroxy-3,4-di- hydronaphthalen-1(2H)-one and related compounds. J Enz Inhib Med Chem 2003; 18:27-33;Smith H J, Ahmadi M, Nicholls P J, Hassanzadeh M F, Benzyl and Benzylidene tetralins and derivatives. WO 9935115 (1999-07-15).
  • Nijar VCO. Cyrochrome P-450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem 2002;2:261–269.
  • Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 1999;58:1201–1208.
  • Marill J, Cresteil T, Lanotte M, Chabot GG. Identification of human cytochrome P450s involved in the formation of all- trans-retinoic acid principal metabolites. Mol Pharmacol 2000;58:1341–1348.
  • McSorley LC, Daly AK. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 2000;60:517–526.
  • Ray WJ, Bain G, Yao M, Gottlieb DI. CYP26, a novel mammalian cytochrome P450 is induced by retinoic acid and defines a new family. J Biol Chem 1997; 272:18702–18708.
  • Haque M, Andreola F, DeLuca LM. The cloning and characterisation of a novel cytochrome P450 family, CYP26 with specificity toward retinoic acid. Nutrition Rev 1998;56:84 –85.
  • Marikar Y, Wang Z, Duell EA, Petkovich M, Voorhees JJ, Fisher GJ. Retinoic acid receptors regulate expression of retinoic acid 4-hydroxylase that specifically inactivates all-trans retinoic acid in human keratinocyte HaCat cells. J Invest Dermatol 1998;111:434–439.
  • Luu L, Ramshaw H, Tahayato A, Stuart A, Jones G, White J, Petkovich M. Regulation of retinoic acid metabolism. Adv Enzyme Reg 2001;41:159–175.
  • Popa C, Dicker AJ, Dahler A, Saunders NA. Cytochrome P450, CYP26A1, is expressed at low levels in human epidermal keratinocytes and is not retinoic acid inducible. Br J Dermatol 1999;141:460–468.
  • Gundersen TE, Blomhoff R. Qualitative and quantitative liquid chromatographic determination of natural retinoids in biological samples. J Chromatogr A 2001;935:13–43.
  • Lanvers G, Hempel G, Blashke G, Boos J. Simultaneous determination of all-trans-, 13-cis- and 9-cis-retinoic acid, their 4-oxo metabolites and all-trans-retinol in human plasma by high-performance liquid chromatography. J Chromatogr B 1996;685:233–240.
  • Wand Y, Chang WY, Prins GS, van Breemen RB. Simul- taneous determination of all-trans, 9-cis, 13-cis-retinoic acid and retinol in rat prostate using liquid chromatography-mass- spectrometry. J Mass Spectrom 2001;36:882–888.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.